CDK2 Knockout Cell Line (HEK293)

The choice depends on whether you are studying CDK2's role as the canonical S-phase CDK or modeling emerging CDK2 inhibitor pharmacology for cancer therapy. The Knockout line is the standard tool for asking whether CDK2 is required for these processes — CDK2 partners with cyclin E (G1/S) and cyclin A (S-phase) to drive DNA replication and S-phase progression, phosphorylating RB1 (hyperphosphorylation), CDC6, and DNA replication factors; CDK2 has emerged as a cancer therapy target especially for CDK4/6 inhibitor-resistant breast cancer (Cyclin E1/CCNE1-amplified). Overexpression is useful for studying CDK2 gain-of-function effects. Important consideration: CDK2 and CDK1 have overlapping substrates — CDK2 deletion is tolerated in mice (compensated by CDK1) but creates synthetic vulnerabilities in CCNE1-amplified cancers. Rescue with wild-type or kinase-dead CDK2 is the standard specificity control. The knockout is a critical specificity tool for ⭐ tagtociclib (PF-07104091, CDK2-selective inhibitor in clinical development), BLU-222 (CDK2-selective inhibitor), INX-315, and emerging CDK2-selective inhibitors for CCNE1-amplified cancers (ovarian, breast, endometrial cancer).

Primary applications: • S-phase progression: BrdU/EdU incorporation analysis given CDK2's S-phase role. • CCNE1-amplified synthetic vulnerability: in heterologous CCNE1-amplified cancer contexts, characterization of CDK2 dependency. • CDK2-selective inhibitor specificity: critical genetic control for ⭐ tagtociclib (PF-07104091), BLU-222, INX-315 in clinical development for CCNE1-amplified cancers. • Cyclin E/A binding: in vitro and cellular CDK2-Cyclin E/A kinase activity. EDITGENE recommends this model for emerging CDK2-selective drug development, particularly for CCNE1-amplified ovarian/breast/endometrial cancers.

Yes. CDK2 rescue experiments are well-established for emerging CDK2 drug research: • Construct design: use a codon-modified CDK2 sequence with a small C-terminal tag (FLAG, HA). CDK2 has the canonical CDK architecture (PSTAIRE, T-loop with T160 activation site) — preserve all elements. • Kinase-dead rescue: K33R mutation in the ATP-binding lysine abolishes catalytic activity. • Functional readout: rescue should restore Cyclin E/A-CDK2 kinase activity, phospho-RB1 hyperphosphorylation, and S-phase progression. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for emerging CDK2-selective drug development.